1H-Indene-3-acetic acid,5-fluoro-2-methyl-1-[[4-(methylsulfonyl)phenyl]methylene]-, (1Z)-
| Title | Journal |
|---|---|
| Structural analysis of sulindac as an inhibitor of aldose reductase and AKR1B10. | Chemico-biological interactions 20150605 |
| Nitric oxide donor exisulind is an effective inhibitor of murine photocarcinogenesis. | Photochemistry and photobiology 20120901 |
| A prospective, controlled phase II study of neoadjuvant exisulind therapy before radical prostatectomy: effect on apoptosis. | Urology 20120801 |
| Assessment of the involvement of oxidative stress and Mitogen-Activated Protein Kinase signaling pathways in the cytotoxic effects of arsenic trioxide and its combination with sulindac or its metabolites: sulindac sulfide and sulindac sulfone on human leukemic cell lines. | Medical oncology (Northwood, London, England) 20120601 |
| The molecular basis for inhibition of sulindac and its metabolites towards human aldose reductase. | FEBS letters 20120102 |
| Regulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by non-steroidal anti-inflammatory drugs (NSAIDs). | Prostaglandins & other lipid mediators 20111101 |
| Sulindac and its metabolites: sulindac sulfide and sulindac sulfone enhance cytotoxic effects of arsenic trioxide on leukemic cell lines. | Toxicology in vitro : an international journal published in association with BIBRA 20110801 |
| Studies on the metabolism and biological activity of the epimers of sulindac. | Drug metabolism and disposition: the biological fate of chemicals 20110601 |
| Optimisation and validation of a fast HPLC method for the quantification of sulindac and its related impurities. | Journal of pharmaceutical and biomedical analysis 20110325 |
| [Antitumor effects of sulindac in ovarian cell cultures]. | Ginekologia polska 20110301 |
| Sulindac sulfide reverses aberrant self-renewal of progenitor cells induced by the AML-associated fusion proteins PML/RARα and PLZF/RARα. | PloS one 20110101 |
| Therapeutic potential of sulindac hydroxamic acid against human pancreatic and colonic cancer cells. | European journal of medicinal chemistry 20101101 |
| Sulindac and its metabolites inhibit multiple transport proteins in rat and human hepatocytes. | The Journal of pharmacology and experimental therapeutics 20100801 |
| Sulindac metabolites induce proteosomal and lysosomal degradation of the epidermal growth factor receptor. | Cancer prevention research (Philadelphia, Pa.) 20100401 |
| Curcumin potentiates the pro-apoptotic effects of sulindac sulfone in colorectal cancer. | Expert opinion on investigational drugs 20100401 |
| Sulindac sulfone induces a decrease of beta-catenin in HNSCC. | Anticancer research 20100201 |
| 15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is up-regulated by flurbiprofen and other non-steroidal anti-inflammatory drugs in human colon cancer HT29 cells. | Archives of biochemistry and biophysics 20090715 |
| Synthesis, pharmacological evaluation and docking studies of new sulindac analogues. | European journal of medicinal chemistry 20090501 |
| A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 30104. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20090201 |
| Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080901 |
| A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004. | Clinical genitourinary cancer 20080901 |
| Activation of protein kinase G Increases the expression of p21CIP1, p27KIP1, and histidine triad protein 1 through Sp1. | Cancer research 20080701 |
| Interactions of sulindac and its metabolites with phospholipid membranes: an explanation for the peroxidation protective effect of the bioactive metabolite. | Free radical research 20080701 |
| Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). | Journal of medicinal chemistry 20080612 |
| The proapoptotic effects of sulindac, sulindac sulfone and indomethacin are mediated by nucleolar translocation of the RelA(p65) subunit of NF-kappaB. | Oncogene 20080417 |
| Sulindac and its metabolites induce carcinogen metabolizing enzymes in human colon cancer cells. | International journal of cancer 20080301 |
| A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitro. | Cancer chemotherapy and pharmacology 20080201 |
| Malignant transformation of normal enterocytes following downregulation of Bak expression. | Digestion 20080101 |
| Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence. | Clinical cancer research : an official journal of the American Association for Cancer Research 20071001 |
| Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20071001 |
| Sulindac sulfone modulates beta-catenin in human cholesteatoma cell culture. | Archives of medical research 20070501 |
| Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3epsilon. | Cancer research 20070401 |
| Alpha-tocopheryl succinate sensitizes human colon cancer cells to exisulind-induced apoptosis. | Apoptosis : an international journal on programmed cell death 20070201 |
| Differential activity of sulindac metabolites against squamous cell carcinoma of the head and neck is mediated by p21waf1/cip1 induction and cell cycle inhibition. | Cancer biology & therapy 20070101 |
| Effects of oral dosing paradigms (gavage versus diet) on pharmacokinetics and pharmacodynamics. | Chemico-biological interactions 20061201 |
| Gene expression profiling in R-flurbiprofen-treated prostate cancer: R-Flurbiprofen regulates prostate stem cell antigen through activation of AKT kinase. | Biochemical pharmacology 20061115 |
| Exisulind induces apoptosis in advanced myelodysplastic syndrome (MDS) and acute myeloid leukaemia/MDS. | British journal of haematology 20061101 |
| p38MAPK inhibitor SB203580 sensitizes human SNU-C4 colon cancer cells to exisulind-induced apoptosis. | Oncology reports 20061101 |
| 15-Hydroxyprostaglandin-dehydrogenase is involved in anti-proliferative effect of non-steroidal anti-inflammatory drugs COX-1 inhibitors on a human medullary thyroid carcinoma cell line. | Prostaglandins & other lipid mediators 20061001 |
| A phase II trial of carboplatin and gemcitabine with exisulind (IND #65,056) in patients with advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group study (E1501). | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20060901 |
| Chemopreventive alteration of the cell-cell adhesion in head and neck squamous cell cancer. | Oncology reports 20060801 |
| Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma. | American journal of clinical oncology 20060801 |
| Capillary electrophoresis combining field-amplified sample stacking and electroosmotic flow suppressant for analysis of sulindac and its two metabolites in plasma. | Journal of chromatography. A 20060630 |
| Sulindac sulfide and exisulind inhibit expression of the estrogen and progesterone receptors in human breast cancer cells. | Clinical cancer research : an official journal of the American Association for Cancer Research 20060601 |
| Apoptosis: a relevant tool for anticancer therapy. | Annals of oncology : official journal of the European Society for Medical Oncology 20060601 |
| Exisulind and guanylyl cyclase C induce distinct antineoplastic signaling mechanisms in human colon cancer cells. | Molecular cancer therapeutics 20060501 |
| The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. | Bioorganic & medicinal chemistry letters 20060415 |
| Sporadic adenomatous polyp regression with exisulind is effective but toxic: a randomised, double blind, placebo controlled, dose-response study. | Gut 20060301 |
| Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancer. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20060301 |
| Induction of spermidine/spermine N1-acetyltransferase (SSAT) by aspirin in Caco-2 colon cancer cells. | The Biochemical journal 20060215 |
| Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis. | Investigational new drugs 20060101 |
| The sulindac derivatives OSI-461, OSIP486823, and OSIP487703 arrest colon cancer cells in mitosis by causing microtubule depolymerization. | Molecular cancer therapeutics 20060101 |
| Exisulind in the treatment of prostate cancer. | Expert review of anticancer therapy 20051201 |
| Sulindac sulfone is most effective in modulating beta-catenin-mediated transcription in cells with mutant APC. | Annals of the New York Academy of Sciences 20051101 |
| Activation of protein kinase G up-regulates expression of 15-lipoxygenase-1 in human colon cancer cells. | Cancer research 20050915 |
| Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. | Drug metabolism and disposition: the biological fate of chemicals 20050701 |
| The nonsteroidal anti-inflammatory drug Exisulind selectively induces apoptosis via JNK in secondary acute myeloid leukemia after myelodysplastic syndrome. | Cell cycle (Georgetown, Tex.) 20050601 |
| A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer. | BJU international 20050501 |
| A phase I/II study of exisulind in combination with docetaxel/carboplatin in patients with metastatic non-small-cell lung cancer. | Clinical lung cancer 20050501 |
| Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. | Molecular cancer therapeutics 20050201 |
| Nobiletin, a citrus flavonoid, down-regulates matrix metalloproteinase-7 (matrilysin) expression in HT-29 human colorectal cancer cells. | Bioscience, biotechnology, and biochemistry 20050201 |
| Inhibition of extracellular-signal regulated kinases 1/2 is required for apoptosis of human colon cancer cells in vitro by sulindac metabolites. | Cancer research 20041115 |
| Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. | Clinical cancer research : an official journal of the American Association for Cancer Research 20041115 |
| A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20041101 |
| Suppression of angiogenic activity of sera from diabetic patients with non-proliferative retinopathy by compounds of herbal origin and sulindac sulfone. | International journal of molecular medicine 20041001 |
| Glutathione-S-transferase P1-1 protects aberrant crypt foci from apoptosis induced by deoxycholic acid. | Gastroenterology 20040801 |
| Effect of nonsteroidal anti-inflammatory drugs on beta-catenin protein levels and catenin-related transcription in human colorectal cancer cells. | British journal of cancer 20040705 |
| Activation of protein kinase G is sufficient to induce apoptosis and inhibit cell migration in colon cancer cells. | Cancer research 20040601 |
| Exisulind: Aptosyn, FGN 1, Prevatac, sulindac sulfone. | Drugs in R&D 20040101 |
| Combinatorial chemoprevention: efficacy of lovostatin and exisulind on the formation and progression of aberrant crypt foci. | Anticancer research 20040101 |
| Cox-2 is needed but not sufficient for apoptosis induced by Cox-2 selective inhibitors in colon cancer cells. | Apoptosis : an international journal on programmed cell death 20031201 |
| Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer. | The Journal of biological chemistry 20031128 |
| The metabolism of sulindac enhances its scavenging activity against reactive oxygen and nitrogen species. | Free radical biology & medicine 20031101 |
| Exisulind and related compounds inhibit expression and function of the androgen receptor in human prostate cancer cells. | Clinical cancer research : an official journal of the American Association for Cancer Research 20031015 |
| Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030915 |
| Sulindac metabolites induce caspase- and proteasome-dependent degradation of beta-catenin protein in human colon cancer cells. | Molecular cancer therapeutics 20030901 |
| Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival. | Molecular cancer therapeutics 20030501 |
| Chemoprevention of colorectal cancer: slow, steady progress. | Cleveland Clinic journal of medicine 20030401 |
| What's new in the treatment of advanced prostate cancer? | European journal of cancer (Oxford, England : 1990) 20030101 |
| Exisulind and CP248 induce growth inhibition and apoptosis in human esophageal adenocarcinoma and squamous carcinoma cells. | Journal of experimental therapeutics & oncology 20030101 |
| Pro-apoptotic actions of exisulind and CP461 in SW480 colon tumor cells involve beta-catenin and cyclin D1 down-regulation. | Biochemical pharmacology 20021101 |
| Rapid development of colitis in NSAID-treated IL-10-deficient mice. | Gastroenterology 20021101 |
| Benzylamide sulindac analogues induce changes in cell shape, loss of microtubules and G(2)-M arrest in a chronic lymphocytic leukemia (CLL) cell line and apoptosis in primary CLL cells. | Cancer research 20021015 |
| Vasodilator-stimulated phosphoprotein (VASP) phosphorylation provides a biomarker for the action of exisulind and related agents that activate protein kinase G. | Molecular cancer therapeutics 20020801 |
| Sulindac derivative-induced apoptosis in a human umbilical vein endothelial cell line ECV304. | Chinese medical journal 20020701 |
| Novel clinical trials in androgen-independent prostate cancer. | Clinical prostate cancer 20020601 |
| PPARgamma-mediated antineoplastic effect of NSAID sulindac on human oral squamous carcinoma cells. | International journal of cancer 20020420 |
| Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells. | The Journal of biological chemistry 20020419 |
| CP248, a derivative of exisulind, causes growth inhibition, mitotic arrest, and abnormalities in microtubule polymerization in glioma cells. | Molecular cancer therapeutics 20020401 |
| Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20020301 |
| GATA-6 transcriptional regulation of 15-lipoxygenase-1 during NSAID-induced apoptosis in colorectal cancer cells. | Cancer research 20020215 |
| Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer. | Seminars in oncology 20020201 |
| Sulindac induces apoptosis, inhibits proliferation and activates caspase-3 in Hep G2 cells. | Anticancer research 20020101 |
| beta-Catenin signaling: therapeutic strategies in oncology. | Cancer biology & therapy 20020101 |
| Progression and NSAID-induced apoptosis in malignant melanomas are independent of cyclooxygenase II. | Melanoma research 20011201 |
| Cyclic GMP-dependent protein kinase activation and induction by exisulind and CP461 in colon tumor cells. | The Journal of pharmacology and experimental therapeutics 20011101 |
| Exisulind, a selective apoptotic antineoplastic drug. | Expert opinion on investigational drugs 20011001 |
| Sulindac sulfide-induced apoptosis involves death receptor 5 and the caspase 8-dependent pathway in human colon and prostate cancer cells. | Cancer research 20010915 |
| Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy. | The Journal of urology 20010901 |
| Docetaxel and exisulind in hormone-refractory prostate cancer. | Seminars in oncology 20010801 |
| Sulindac-associated choledocholithiasis. | The American journal of gastroenterology 20010701 |
| Rat colorectal tumours treated with a range of non-steroidal anti-inflammatory drugs show altered cyclooxygenase-2 and cyclooxygenase-1 splice variant mRNA expression levels. | Carcinogenesis 20010601 |
| Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. | Cancer research 20010515 |
| Protein kinase G activates the JNK1 pathway via phosphorylation of MEKK1. | The Journal of biological chemistry 20010511 |
| Sulindac and its derivatives: a novel class of anticancer agents. | Current opinion in investigational drugs (London, England : 2000) 20010501 |
| Proapoptotic anti-inflammatory drugs. | Urology 20010401 |
| Inhibition of extracellular signal-regulated kinase 1/2 phosphorylation and induction of apoptosis by sulindac metabolites. | Cancer research 20010215 |
| Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. | Cancer research 20010215 |
| Growth-suppressive effect of non-steroidal anti-inflammatory drugs on 11 colon-cancer cell lines and fluorescence differential display of genes whose expression is influenced by sulindac. | International journal of cancer 20001215 |
| Sulindac sulfone inhibits K-ras-dependent cyclooxygenase-2 expression in human colon cancer cells. | Cancer research 20001201 |
| Non-steroidal anti-inflammatory drugs with different cyclooxygenase inhibitory profiles that prevent aberrant crypt foci formation but vary in acute gastrotoxicity in a rat model. | Journal of gastroenterology and hepatology 20001201 |
| Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-Jun NH2-terminal kinase 1. | Clinical cancer research : an official journal of the American Association for Cancer Research 20001001 |
| Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. | Cancer research 20000701 |
| Inhibition of rat colon tumors by sulindac and sulindac sulfone is independent of K-ras (codon 12) mutation. | American journal of physiology. Gastrointestinal and liver physiology 20000201 |
| Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process. | Cancer research 19990715 |